Diagnostic Tool for the Treatment of Diabetes

Diagnostic Tool for the Treatment of Diabetes

Introduction

The disease in question, that is diabetes, is described as a body condition affecting blood glucose level. Diabetes has two classifications. The Type 1 diabetes is that which occurs due to the pancreases not producing any insulin at all to control the sugar levels in the blood. Type two of diabetes occurs in situations where the pancreases produce insulin but in insufficient amounts that are not enough for the sugar control procedures in the body. There is a need for a proper diagnostic tool to be used for the treatment of diabetes for both the adults and the children. The article, “Treatment of patients with type 2 diabetes with Eventide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals” will be reviewed for this report.

Summary of the Research

The major aspect described by the article involves the various treatment models of the patients affected with Diabetes type two. The chosen reading gives a description and an enumerations of the correlation between diabetes and cardiovascular risk outcomes. The article depicts the appropriate care strategies for patients diagnosed with diabetes type two   (Maeloni, DeYoung, Han, Best, & Grimm, 2013). One of the tools identified for helping on the same is the glycemic control, which is useful in the process of reducing the cardiovascular risk factor but leaves the patients affected by diabetes two at risks. The research method utilized by the article involved the analysis of data that was obtained from three different double/open blind-labeled trails. An ethics review board reviewed the whole study in a variety of ways based on the ABI significance and QW metformin. The number of clinical trials that were involved in the research process that this article utilized was four, and the board of ethics also reviewed these.

Most of the information obtained from the studies were in support of the exenatide QW over the metformin mainly based on the HbA1c goals ≤6.5% along with the fasting blood glucose (Meloni, et al., 2013). On the other hand, both sitagliptin and exenatide QW were also examined, and the later was found as being more efficient than the former especially backed with evidence from the ABI favored exenatide QW for each of the HbA1c goals that they had set among all the other goals set. Moreover, when exenatide QW and insulin glargine were compared, the findings of the article show that most of the patients that achieved the goals established by HbA2c were focused on exenatide QW. The administration of these drugs, however, had adverse side effects on the patients including injection site reactions, headaches, diarrhea, nasopharyngitis, and nausea. Moreover, glycemic control was identified as being directly linked to the gain of weight, showing a relationship with hyperglycemia, in particular on the patients under certain medication (Meloni, et al., 2013).

The conclusion of the research article is that the comparison of the commonly used therapies to lower levels of glucose within the body with administration of drugs such as dipeptidy1, basal insulin, biguanides, peptidase-4 inhibitors, among others is important since it helps to accomplish the therapeutic goals as well as provide better facilities for medication on the diabetes type two (American Diabetes Association. 2014). The recommendation to the therapeutic and treatment goals is that they are to be taken seriously to ensure that the rate of the risk of the cardiovascular threat is not that much in the patients (Sung, 2011).

Diabetic Diagnosis Tool

The article identifies that glycemic control is the best diagnostic tool for diabetes two patients, being either the adults or the children. Based on the article, this method is not only safe, but it does not offer any forms of resistance to the body of the patients, and hence the side effects are minimal. This is primarily the reason why this approach was selected (Meloni, et al., 2013).

Conclusion

Diabetes is a condition that affects the level of glucose in the blood and is mainly categorized into two. There is a need for a proper diagnostic tool to be used for the treatment of diabetes for both the adults and the children. The article, “Treatment of patients with type 2 diabetes with Eventide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals” is the article to be reviewed. The major aspect described by the article involves the various treatment models of the patients affected with Diabetes type two. The article describes the reasons why diabetes two is associated with the risk of cardiovascular outcomes depicting the proper ways to care for the patients who may be affected by diabetes two. The conclusion of the research article is that the comparison of the commonly used therapies to lower levels of glucose within the body with administration of drugs such as dipeptidy1, basal insulin, biguanides, peptidase-4 inhibitors, among others is important since it helps to accomplish the therapeutic goals as well as provide better facilities for medication on the diabetes type two.

References

American Diabetes Association. (2014). Standards of medical care in diabetes—2014. Diabetes care37(Supplement 1), S14-S80. From http://care.diabetesjournals.org/content/37/Supplement_1/S14%20.full.pdf+html

Meloni, A. R., DeYoung, M. B., Han, J., Best, J. H., & Grimm, M. (2013). Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovascular diabetology12(1), 48. From https://cardiab.biomedcentral.com/articles/10.1186/1475-2840-12-48

Sung, T. H. (2011). Hemoglobin A1c as a Diagnostic Tool for Diabetes Screening and New-Onset Diabetes Prediction. Retrieved from Diabetes Journals: http://care.diabetesjournals.org/content/diacare/34/4/944.full.pdf

Place this order or similar order and get an amazing discount. USE Discount code “GWEXDDSRGCF10” for 10% discount